Announcement on Changing Signatory Certified Public Accountant
Filed with SSE · · 2 pages · Chinese
Earlier from Sinotherapeutics
- Announcement on Voluntary Disclosure of Obtaining US FDA Approval Number for the Company’s Sitagliptin and Metformin Hydrochloride Sustained-release Tablets
- Announcement on Release of Pledge of Partial Shares Held by Shareholders with Over 5% Shares
- Announcement on Implementation of Semi-annual Dividend Distribution for 2025
- Announcement on Pledge of Partial Shares by Shareholders with Over 5% of Shares
- Announcement on Increasing Estimated Amount of Daily Related Party Transactions in 2025
Later from Sinotherapeutics
- Indicative Announcement on Equity Change of Shareholding Reduction by Shareholder with Over 5% Shares to Less than 5%
- Announcement on Voluntary Disclosure of the Proposed Selection of Products in the National Centralized Drug Procurement
- Report for Q3 2025
- Announcement on Attending Three-Quarter Report Collective Performance Briefing of Listed Companies in Shanghai Jurisdiction in 2025
- Announcement on Voluntary Disclosure of the Renewal and Inclusion of the Company’s Product in the National Medical Insurance Catalog
Follow Sinotherapeutics into a list and get an email when it puts out news.
Follow Sinotherapeutics